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Abstract
Background: Hypermetabolism and muscle wasting fre-
quently occur in patients with severe emphysema. Improving 
respiratory mechanics by bronchoscopic lung volume reduc-
tion (BLVR) might contribute to muscle maintenance by de-
creasing energy requirements and alleviating eating-related 
dyspnoea. Objective: The goal was to assess the impact of 
BLVR on energy balance regulation. Design: Twenty emphy-
sematous subjects participated in a controlled clinical exper-
iment before and 6 months after BLVR. Energy requirements 
were assessed: basal metabolic rate (BMR) by ventilated 
hood, total daily energy expenditure (TDEE) by doubly la-
belled water, whole body fat-free mass (FFM) by deuterium 
dilution, and physical activity by accelerometry. Oxygen satu-
ration, breathing rate, and heart rate were monitored before, 
during, and after a standardized meal via pulse oximetry and 
dyspnoea was rated. Results: Sixteen patients completed fol-
low-up, and among those, 10 patients exceeded the minimal 
clinically important difference of residual volume (RV) reduc-
tion. RV was reduced with median (range) 1,285 mL (−2,430, 
−540). Before BLVR, 90% of patients was FFM-depleted de-
spite a normal BMI (24.3 ± 4.3 kg/m2). BMR was elevated by 
130%. TDEE/BMR was 1.4 ± 0.2 despite a very low median 
(range) daily step count of 2,188 (739, 7,110). Following BLVR, 
the components of energy metabolism did not change sig-
nificantly after intervention compared to before interven-
tion, but BLVR treatment decreased meal-related dyspnoea 
(4.1 vs. 1.7, p = 0.019). Conclusions: Impaired respiratory me-
chanics in hyperinflated emphysematous patients did not ex-
plain hypermetabolism. Clinical Trial Registry Number: 
NCT02500004 at www.clinicaltrial.gov.
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Only very recently, a new chronic obstructive pulmo-
nary disease (COPD) phenotype titled “multi-organ loss 
of tissue” has been proposed. This phenotype includes 
those with accelerated emphysema progression and en-
hanced tissue loss in other extrapulmonary compart-
ments, including muscle and adipose tissue. Disturbed 
tissue maintenance is associated with worse clinical out-
comes [1] and might be the result of changes in whole 
body energy expenditure.
Whole-body energy expenditure can be distinguished 
into basal metabolic rate (BMR), diet-induced thermo-
genesis, and physical activity-induced energy expendi-
ture. BMR is primarily determined by fat-free mass (FFM) 
and comprises the largest part of total daily energy expen-
diture (TDEE) [2]. Diet-induced thermogenesis is ±10% 
of TDEE [3], and physical activity-induced energy expen-
diture largely depends on physical activity level [4]. 
Whole-body energy expenditure can only be measured 
over a prolonged period in daily life using doubly labelled 
water [5]. This stable isotope methodology is very expen-
sive and requires analytical technology that is available in 
a limited number of centres worldwide.
In COPD, an increased BMR relative to predicted val-
ues has repeatedly been demonstrated [6], which is more 
aggravated in weight-losing patients [6] and in those with 
emphysema [7]. Although hypermetabolic at rest, COPD 
patients do not exhibit increased diet-induced thermo-
genesis [8]. Besides the proposed triggers for hyperme-
tabolism including activation of brown adipose tissue, in-
flammation, and increased whole body protein turnover, 
impaired lung mechanics might also result in hyperme-
tabolism [9]. Emphysema is hallmarked by a reduction in 
lung elastic recoil and progressive hyperinflation, result-
ing in elevated airway resistance and contributing to im-
paired lung mechanics [10]. This results in an increased 
workload of breathing (mL oxygen cost per litre ventila-
tion) [11]. The increased breathing workload has shown 
to be more pronounced in patients with low body weight 
and correlated with the degree of hyperinflation [12].
Pharmacological interventions may alleviate dyspnoea, 
reduce exercise limitation, and improve quality of life in 
COPD by decreasing airway resistance and reducing hy-
perinflation. However, response is limited in patients with 
predominant emphysema [13]. In selected severe emphy-
sematous patients, bronchoscopic lung volume reduction 
(BLVR) is an additional treatment option that results in 
marked benefits in terms of pulmonary function, dys-
pnoea, exercise capacity, and also physical activity [14, 
15]. Furthermore, in a recent post hoc analysis of the 
STELVIO trial [15], we illustrated a significant increase in 
body weight, skeletal muscle, and fat tissue, suggesting a 
positive effect on energy balance regulation [16].
BLVR is a unique model to test the influence of lung 
mechanics on energy balance regulation, as it diminishes 
thoracic hyperinflation, reduces breathing frequency, 
and reduces mechanical constraints on lung volume ex-
pansion, thereby improving ventilatory mechanics [17]. 
Efficacy of this treatment highly depends on advanced 
patient selection to identify responders to the treatment 
and thereby creating a homogeneous study population.
We hypothesize that a decline in breathing workload 
following BLVR would decrease energy expenditure, 
which might positively influence components and deter-
minants of energy balance. Second, BLVR may also im-
prove dietary intake by alleviating eating associated dys-
pnoea and meal-related oxygen desaturation [18].
Methods
Participants
Twenty patients with advanced emphysema, an identified tar-
get lobe with confirmed absence of collateral ventilation by the 
Chartis measurement, who underwent BLVR treatment using 
1-way endobronchial valves were included in this study. Patients 
were recruited from the Maastricht University Medical Centre 
(MUMC+) and University Medical Centre Groningen (UMCG) in 
the Netherlands from September 2016 until April 2017. The Ethics 
Committee of Maastricht University Medical Centre approved the 
study protocol, and all participants provided written informed 
consent. Procedures were conducted according to the principles of 
the Declaration of Helsinki. The trial was registered at Clinical-
Trial.gov (NCT02500004).
Study Design
The study design is shown in Figure 1. Prior to BLVR treat-
ment, patients underwent a 2-week assessment period.
At day 0, patients were visited at home and received a dose of 
doubly labelled water. They were also instructed to collect urine 
samples for assessment of TDEE and to wear an accelerometer for 
registration of physical activity. Furthermore, patients were asked 
to record their dietary intake in order to assess if they were in a 
state of stable energy balance. On day 15, fasted-state urine and 
blood samples were collected; weight, height, and BMR were as-
sessed; and a meal test was performed (vide infra). This 2-week 
assessment period was repeated 6 months after BLVR treatment.
Body Composition
Body height was determined to the nearest 0.5 cm while the 
subjects were standing barefoot. Weight was assessed with a beam 
scale to the nearest 0.1 kg while the subjects were standing barefoot 
and in light clothing. FFM was calculated from total body water 
assessment using the deuterium dilution technique, assuming a 
hydration fraction of FFM of 73%.





BMR was measured by indirect calorimetry using a ventilated 
hood (EZCAL; Maastricht Instruments, Maastricht, the Nether-
lands and COSMED QUARK; TulipMed B.V., The Netherlands). 
Patients received their maintenance inhalation according to their 
normal habits. The time interval between medication use and start 
of indirect calorimetry was documented. During the second 
2-week assessment period 6 months following BLVR treatment, 
the same time interval between medication use and start of indirect 
calorimetry was employed. Patients were in a fasting state for at 
least 10 h and had a period of 30-min bed rest prior to the measure-
ment during which subjects were lying on bed in supine position. 
After stabilization, BMR was recorded during a period of 30 min. 
BMR was calculated from oxygen consumption (VO2) and carbon 
dioxide (VCO2) production using the abbreviated Weir formula 
[19]. BMR was also predicted using the equation from Slinde et al. 
[20], which was especially designed for COPD patients.
Total Daily Energy Expenditure
TDEE was determined by the doubly labelled water technique 
over two 2-week periods (before and after BLVR treatment) ac-
cording to the Maastricht protocol [21]. In the evening, prior to 
dosing, a urine sample was collected for determination of back-
ground isotope enrichment. Each patient received a weighted oral 
dose of water labelled with deuterium and oxygen-18. The given 
dose was calculated based on the subjects’ total body water, which 
was estimated based on BMI, age, and gender. Subjects received a 
dose of 2.5 g/L total body water containing 250 ppm deuterium 
and 2,200 ppm oxygen-18. After overnight equilibration, a second 
urine sample was collected from the second morning voiding. Ad-
ditional urine samples were collected in the evening of days 1, 7, 
and 14 and in the morning of days 8 and 15. TDEE was calculated 
by the linear regression from the difference between elimination 
constants of deuterium and oxygen-18.
Physical Activity
Actigraph GTX3 accelerometers (Actigraph, Pensacola, FL, 
USA) were used to assess the physical activity level. This activity 
monitor has been validated against activity-related energy expen-
diture measured by doubly labelled water in patients with different 
stages of COPD [22]. The triaxial accelerometers were attached to 
the lower back with an elastic belt and worn for 7 consecutive days. 
Subjects were instructed to wear the accelerometer during the time 
they were not asleep, except when showering or bathing. Only days 
with ≥8 h of wear time were accepted as valid days. Energy expen-
diture for activities was calculated by (0.9 × TDEE) − BMR, assum-
ing a diet-induced thermogenesis of 10% of TDEE.
Dietary Intake
Food intake was recorded by a food diary for 2 week days and 
1 weekend day to estimate baseline energy balance.
Meal Test
On the measurement day at the hospital, subjects received a 
standardized breakfast with wheat bread, butter, eggs, and milk. 
This meal contained a total of 502 kcal derived from protein (24%), 
carbohydrate (28%), and fat (48%). Oxygen saturation, breathing 
rate, and heart rate were monitored before, during, and after the 
breakfast via pulse oximetry. Before and immediately after the 
meal, dyspnoea was rated using the Borg Dyspnoea Scale.
Systemic Inflammatory Status
High-sensitive C-reactive protein (hsCRP) was assessed from 
frozen stored plasma collected from a venepuncture after over-
night fasting.
Statistics
Descriptive statistics of demographic and clinical variables 
were obtained. Means (±SD) were provided for continuous nor-
mally distributed variables, medians (interquartile range) for con-
tinuous not normally distributed variables, and percentages were 
shown for categorical variables. Baseline and 6-month follow-up 
measurements were compared with a paired-sample t test or Wil-
coxon signed-rank test. All analyses were performed using SPSS 
statistical software (SPSS Statistics for Windows, version 24.0; 
IBM, Armonk, NY, USA). Results with 2-sided p values (<0.05) 
were considered statistically significant.
Results
Patient Characteristics
Twenty patients (7 men, 13 women) with severe em-
physema (n = 10 MUMC+ and n = 10 UMCG) were en-
rolled in this study, and 16 patients completed the follow-
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up. Reasons for drop out were patients’ decision due to 
deterioration in health (n = 2), patients’ decision due to 
lack of efficacy of BLVR treatment (n = 1), and diagnosis 
of bladder cancer (n = 1). In 4 of the 16 patients who com-
pleted follow-up, endobronchial valves were removed 
due to granulation tissue around endobronchial valves 
(n = 2), torsion bronchus (n = 1), and recurrent pneumo-
thorax (n = 1) (Fig. 2).
Baseline characteristics are depicted in Table  1. The 
study population represented a COPD population with 
normal BMI (24.1 ± 4.4 kg/m2) and low FFM (FFM index: 
males 15.1 kg/m2 [14.7, 16.2], females 13.5 kg/m2 [12.1, 
18.1]). The prevalence of depletion of FFM, defined as 
FFM index ≤17 kg/m2 for males or ≤15 kg/m2 for females 
[23], was 90%.
Baseline Assessment
At baseline, the mean BMR was 1,537 ± 259 kcal/day, 
which corresponded to 130% of predicted, indicating 
pronounced hypermetabolism. The average TDEE over 2 
weeks was 2,133 ± 294 kcal/day. The average daily TDEE 
of week 1 was not statistically significantly different from 
the average daily TDEE of week 2. Energy expenditure for 
activities was median (range) 275 kcal/day (138, 827) 
(11% of TDEE).
Among those who completed follow-up, from all sub-
jects but 2 (due to an accelerometer device defect), 6.5 ± 
1.1 valid accelerometry days were available with a mean 
of 13 ± 1 h of wear time per day. Median (range) steps per 
day was 2,188 (739, 7,110). Patients spent a significant 
part of the day in sedentary state (79.7% of the wear time 
[56.5, 89.6]) (Table 2).
Systemic inflammation measured by hsCRP was 3.0 ± 
2.7 mg/L. BMR or TDEE was not associated with hsCRP 
or residual volume (RV) (% of predicted) (data not 
shown). Reported dietary intake comprised 2,065 ± 507 
kcal/24 h, which equalled measured TDEE. Patients ex-
perienced more dyspnoea after eating (4.1 ± 1.8 after meal 
vs. 2.1 ± 2.1 before meal, p = 0.013). No significant change 
was shown in oxygen saturation, respiration rate, and 
heart beat rate during the course of the meal (Fig. 3).
Response after BLVR
Not all patients benefited from the BLVR treatment, in 
terms of hyperinflation reduction. We therefore took a 
closer look at the 10 patients who responded beyond the 
MCID for RV reduction of >430 mL [24]. At 6-month 
follow-up, patients significantly improved in RV and 
forced expiratory volume in 1 s, with 1,285 mL (−2,430, 
−540) and 190 mL (10, 390), respectively.
BMR did not significantly change over time (1,537 ± 
259 kcal/day vs. 1,549 ± 231 kcal/day, p = 0.778), and 
patients remained hypermetabolic (BMR was 130% of 
predicted). No changes in TDEE were observed (2,133 
± 294 kcal/day vs. 2,192 ± 480 kcal/day, p = 0.576), in 
accordance with an unaltered physical activity ex-
pressed by mean number of daily steps. Although 6-min 
walk distance increased significantly, the mean step 
Eligibility patients
(n = 29)
- Not willing to participate





- Patients’ decision due to
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FEV1, % predicted 23.3±6.6
FVC, % predicted 76.2±15.9
FEV1/FVC 28.5±6.3
RV, % predicted 238.3±38.2









Data are represented as mean ± SD or median (minimum-max-
imum). FEV1, forced expiratory volume in 1 s; FVC, forced vital 
capacity; RV, residual volume; TLC, total lung capacity; FFM, fat-
free mass; FFMI, fat-free mass index.
Fig. 2. Study flowchart.




count and activity-induced energy expenditure did not 
change over time. hsCRP also remained unchanged 
(Table 2).
A significant effect of BLVR treatment on meal-related 
dyspnoea was observed. Compared to baseline, meal-re-
lated dyspnoea after the meal was significantly lower after 
BLVR treatment (1.7 ± 2.4 vs. 4.1 ± 1.8, p = 0.019). No 
changes were found in oxygen saturation, respiration 
rate, or heart rate during the meal (Fig. 3).
Discussion
This is the first study presenting a comprehensive 
analysis of energy balance in a homogeneous group of 
patients with severe emphysema and investigating the ef-
fect of BLVR. In contrast to our hypothesis, a median re-
duction of hyperinflation with 25% did not decrease BMR 
or TDEE adjusted for physical activity level. Eating-relat-
ed dyspnoea, however, was diminished.
Table 2. Clinical variables and components of energy balance at baseline and 6 months after BLVR treatment 
(n = 10)
Baseline After BLVR p value
Lung function and symptom burden
FEV1, % of predicted value 27.5±6.9 34.9±8.3 0.003
FVC, % of predicted value 74.4±15.0 95.1±17.1 <0.001
FEV1/FVC 30.5±7.2 29.5±5.6 0.591
RV, % of predicted value 236.2±37.6 181.3±27.5 <0.001
TLC, % of predicted value 135.0±20.0 125.1±14.7 0.007
RV/TLC 65.8±6.2 51.3±6.1 <0.001
COPD assessment test, points 18.6±3.4 14.3±5.8 0.022
6MWD, m 378±98 427±84 0.030
Body composition
Weight, kg 71.4±17.4 73.0±18.7 0.096
BMI, kg/m2 24.3±4.3 24.8±5.0 0.127
FFM, kg 40.4 (32.2–57.4) 41.1 (29.4–60.2) 0.074
FFMI, kg/m2
Male 15.5 (14.7–16.2) 16.6 (15.5–18.6) 0.068
Female 13.2 (12.4–17.6) 13.6 (12.1–17.3) 0.600
Energy expenditure
VCO2, mL/min 179.5±26.1 180.5±28.6 0.854
VO2, mL/min 224.7±40.0 224.0±3.1 0.903
RQ 0.81±0.07 0.81±0.05 0.916
BMR measured, kcal/day 1,537±259 1,549±231 0.778
BMR predicted, kcal/day 1,213±155 1,245±189 0.103
BMR measured/BMR predicted ratio 1.3±0.2 1.2±0.1 0.655
TDEE, kcal/24 h 2,133±294 2,192±480 0.576
TDEE/BMR ratio 1.4±0.2 1.4±0.3 0.934
Energy expenditure for activities, kcal/day 275 (138–827) 397 (18–1,262) 0.694
Energy expenditure for activities/TDEE ratio 0.2±0.1 0.2±0.1 0.995
Physical activity level
Mean steps/day 2,188 (739–7,110) 2,429 (990–6,983) 0.161
Time spent in sedentary PA, % of wear time 79.7 (56.5–89.6) 79.4 (52.7–84.2) 0.123
Time spent in lifestyle PA, % of wear time 17.6 (10.1–34.2) 18.6 (14.1–37.9) 0.123
Time spent in MVPA, % of wear time 0.0 (0.0–1.1) 0.2 (0.0–1.4) 0.028
Inflammation
hsCRP, mg/L 3.0±2.7 2.5±1.8 0.463
Data are represented as mean ± SD, or median (minimum-maximum). Values in bold are statistically sig-
nificant. COPD Assessment Test, missing n = 2 FEV1, forced expiratory volume in 1 s; FVC, forced vital capac-
ity; RV, residual volume; TLC, total lung capacity; FFM, fat-free mass; FFMI, fat-free mass index; 6MWD, 6-min 
walk distance; MVPA, moderate-to-vigorous physical activity; PA, physical activity; BMR, basal metabolic rate; 





In line with the “multiorgan loss of tissue” phenotype 
[1], we observed a very high prevalence of FFM depletion 
indicative for disturbed muscle maintenance. Nearly all 
patients were FFM-depleted, but this was disproportion-
ate to the FM as the majority of patients fell within a nor-
mal BMI range. Before BLVR, BMR was very high, up to 
130% of predicted and energy expenditure for physical 
activities was very low (11%). This implies that in this pa-
tient group and at this stage of the disease, fat mass regu-
lation is primarily determined by the balance between en-
ergy intake and whole body energy requirements and less 
or not yet by fat catabolism (i.e., increased lipolysis or 
brown adipose tissue activation). The normal BMI in this 
population hides FFM depletion, emphasizing the impor-
tance of body composition assessment for estimation of 
metabolic risk as proposed by the European Respiratory 
Society Task Force on nutritional assessment and therapy 
in COPD [25].
No studies to date have investigated the effect of lung 
volume reduction on TDEE, but a few studies previously 
reported the effect of lung volume reduction surgery on 
BMR. Mineo et al. [26] showed a reduction of BMR with 
5%, while Takayama et al. [27] observed no change in 
BMR. The degree of hyperinflation reduction was com-
parable to our cohort. Nevertheless, one needs to con-
sider that although our patients improved importantly 
after intervention, they still remain severely hyperinflated 
with a mean RV of 181% of predicted.
A contributor to BMR is whole body protein turnover, 
which explained approximately 20% of the between-sub-
ject variation of BMR in healthy young individuals [28]. 
Also in COPD, increased rates of whole body protein 
turnover have been reported [29, 30], which is associated 
with BMR [31]. Increased muscle turnover signalling was 
accompanied with elevated myogenic signalling [32], 
which was most prominent in patients with FFM deple-
tion. Therefore, persistence of high BMR after BLVR 
might be the result of energy cost of protein anabolism, 
supported by increased muscle mass observed previously 
in chest CT scans [16].
In the absence of catabolic drivers, fat mass is primar-
ily regulated by the balance between energy intake and 
energy metabolism. In line with others [33, 34], our pa-
tients experienced an eating induced increase in dys-
pnoea. Vermeeren et al. [33] reported the effects of differ-
ent meals on dyspnoea sensation and found a significant-
ly greater increase in dyspnoea after ingestion of a fat-rich 
meal than after a carbohydrate-rich meal. Here, we show 
for the first time that dyspnoea after the same, standard-
ized meal was significantly less following BLVR. In line 
with 2 other studies, these effects could not be explained 
by changes in meal-related oxygen saturation [18, 33].
Systemic inflammation has been proposed as putative 
trigger for hypermetabolism, in particular during acute 
exacerbations [35, 36]. Indeed, elevated CRP levels have 













































































Fig. 3. Borg Dyspnoea Score (a), Borg Dyspnoea Score, oxygen saturation, respiration rate, and heart rate before, 
during, and after completion of a standardized meal, before, and after bronchoscopic lung volume reduction 
(BLVR) treatment (n = 10) (b). Data are presented as mean values (±standard deviation).




stable COPD [37, 38]. In this study, CRP levels were 
slightly elevated but did not change after BLVR.
The strength of this prospective well-controlled clini-
cal proof of concept study comes from the well-defined 
patient cohort and from the use of gold standard methods 
to assess body composition, BMR, and TDEE. We recog-
nize that the study power was based on detection of 
changes in energy metabolism in relation to changes in 
lung function but not on changes in body composition. 
The technique of pulse oximetry has the advantage of 
providing a continuous and non-invasive measurement 
of oxygen saturation. However, this technique is limited 
by a poorer accuracy of 1–3% when compared to arterial 
blood sampling [39]. To conclude, the present work 
showed that impaired respiratory mechanics in hyperin-
flated emphysematous patients did not explain hyperme-
tabolism.
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